37 completed. 37 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 37 | Completed 37 |
| Phase 2 | 9 | Completed 9 |
Follow Malabsorption Syndromes: new trials by email Literature Review of Malabsorption Syndromes trials Research Report on Malabsorption Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease HB-2121 - Celiac Disease, Healthy | Phase 1 | Completed | Nielsen Fernandez-Becker | 18 | 2025-08-26 | 2026-07-28 |
| A Study of PJ009 in Healthy Adult Volunteers PJ009, Placebo - Short Bowel Syndrome | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 24 | 2023-02-28 | 2024-07-29 |
| Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients DONQ52, Placebo - Celiac Disease | Phase 1 | Completed | Chugai Pharmaceutical | 56 | 2022-09-19 | 2025-01-31 |
| Study of NST-6179 in Healthy Subjects NST 6179, Placebo - Short Bowel Syndrome, Parenteral Nutrition Associated Liver Disease | Phase 1 | Completed | NorthSea Therapeutics B.V. | 70 | 2021-11-11 | 2024-06-24 |
| Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease Teriflunomide Oral Tablet - Celiac Disease | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 15 | 2021-04-16 | 2025-05-16 |
| PTG-100 for Patients With Celiac Disease PTG-100, Placebo - Celiac Disease | Phase 1 | Completed | Nielsen Fernandez-Becker | 12 | 2021-02-26 | 2022-05-23 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole GSK3915393 Capsules, GSK3915393 Solution for Infusion, Placebo capsules - Celiac Disease, Coeliac Disease | Phase 1 | Completed | GlaxoSmithKline | 65 | 2020-11-04 | 2023-05-09 |
| Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis CALY-002, Placebo - Eosinophilic Esophagitis, Celiac Disease | Phase 1 | Completed | Calypso Biotech BV | 73 | 2020-09-28 | 2024-04-09 |
| Assessment of KAN-101 in Celiac Disease (ACeD) KAN-101, Placebo - Celiac Disease | Phase 1 | Completed | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 41 | 2020-01-21 | 2024-08-06 |
| Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support FE203799 GLP-2 analogue, FE203799 Placebo GLP-2 analogue - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-08 | 2024-10-26 |
| Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency FE203799 - SBS - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-02 | 2024-10-24 |
| Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease Nexvax2, Placebo - Celiac Disease, Intestinal Disease | Phase 1 | Completed | ImmusanT, Inc. | 14 | 2018-05-01 | 2018-09-20 |
| Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects RP-G28 - Lactose Intolerance | Phase 1 | Completed | Ritter Pharmaceuticals, Inc. | 14 | 2018-03-09 | 2018-08-08 |
| Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease TIMP-GLIA - Celiac Disease | Phase 1 | Completed | Takeda | 23 | 2018-01-23 | 2020-06-05 |
| Hookworm Therapy for Coeliac Disease Gluten micro-challenge, Inadvertent gluten challenge, Moderate gluten challenge - Celiac Disease | Phase 1 | Completed | James Cook University, Queensland, Australia | 54 | 2016-09-01 | 2020-02-13 |
| A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease Placebo, RO5459072 - Celiac Disease | Phase 1 | Completed | Hoffmann-La Roche | 19 | 2016-03-06 | 2017-08-25 |
| Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency Stelara (ustekinumab) - Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2015-10-19 | 2020-08-24 |
| Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease Nexvax2, Nexvax2 placebo - Celiac Disease | Phase 1 | Completed | ImmusanT, Inc. | 38 | 2015-08-01 | 2018-12-24 |
| Oral AGY for Celiac Disease AGY - Celiac Disease | Phase 1 | Completed | Igy Inc. | 10 | 2014-05-01 | 2019-12-13 |
| Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients. BL-7010, Placebo - Celiac Disease | Phase 1 / Phase 2 | Completed | BioLineRx, Ltd. | 40 | 2013-12-01 | 2017-08-18 |
Showing 20 of 37. Sign in to see all of them.
Celiac Disease (24) · Short Bowel Syndrome (7) · Intestinal Diseases (2) · Ancylostomiasis (1) · Autoimmune Diseases (1) · Cerebral Palsy (1) · Cholestasis (1) · Common Variable Immunodeficiency (1) · Dermatitis Herpetiformis (1) · Diarrhea (1) · Digestive System Diseases (1) · Eosinophilic Esophagitis (1) · Exocrine Pancreatic Insufficiency (1) · Gastrointestinal Diseases (1)
Digestive System Diseases (35) · Gastrointestinal Diseases (35) · Intestinal Diseases (34) · Nutritional and Metabolic Diseases (30) · Metabolic Diseases (29) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (8) · Postoperative Complications (7) · Immune System Diseases (4) · Central Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Infections (2) · Metabolism, Inborn Errors (2)
ALV003 (2) · Nexvax2 (2) · larazotide acetate (2) · ASP-1 protein, Necator americanus (1) · Aging (1) · Diet, Gluten-Free (1) · Ensure Plus (1) · Hu-Mik-beta-1 monoclonal antibody (1) · Itraconazole (1) · PTG-100 peptide (1) · Pancrelipase (1) · RP-G28 (1) · S-Adenosylmethionine (1) · Ustekinumab (1) · Water (1)
9 Meters Biopharma, Inc. (2) · Alvine Pharmaceuticals Inc. (2) · GlyPharma Therapeutics (2) · ImmusanT, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Nielsen Fernandez-Becker (2) · Amsterdam UMC, location VUmc (1) · Baylor Research Institute (1) · BioLineRx, Ltd. (1) · Boston Children's Hospital (1) · Calypso Biotech BV (1) · Children's Hospital of Michigan (1) · Chongqing Peg-Bio Biopharm Co., Ltd. (1) · Chugai Pharmaceutical (1) · GlaxoSmithKline (1)
United States (16) · Australia (6) · United Kingdom (3) · Denmark (2) · Finland (2) · Germany (2) · Netherlands (2) · New Zealand (2) · Norway (2) · Belgium (1) · Canada (1) · China (1) · Hungary (1) · India (1)
Blake Paterson, MD (2) · Tomasz Masior (2) · Vijaya Pratha, MD (2) · Alexander Loukas, PhD (1) · Ayan Dey, Ph.D (1) · Beth Kirkpatrick, M.D. (1) · Dianne Jones, BAppSc (1) · Eric J McGrath, MD (1) · Greetje J Tack, MD (1) · Gregor Brown, MBBS PhD FRACP (1) · Ilma Korponay-Szabo, M.D., Ph.D. (1) · Ivan J Fuss, M.D. (1) · James Daveson, MBBS FRACP (1)
PMID 17697209, PMID 20650871, PMID 23770843, PMID 24124328, PMID 26134988, PMID 28194449, PMID 29191561, PMID 33722583, PMID 34287970, PMID 37329900, PMID 39739628, PMID 41039829
2015 (1)